Biolytix AG

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

GEM FORLAB gives continuity to the experience of ABLE Biosciences as a global provider of scientific technology and services to the Life Science industry. It delivers solutions to companies of all size and shapes.
GEM FORLAB performs its activities by means of three technology areas:
Organic Chemistry
Mass Spectrometry & Proteomics
Cell and Molecular Biology & Immunoassay

ABLE Biosciences is the Test Facility GLP certified for small and large molecules quantitative analysis in biological matrices by means of Mass Spectrometry, Immunometric assays and qPCR and it is included in OsSC register of Private Laboratories qualified to perform analysis on samples derived from drug clinical trials (phase I-II-III) in compliance with GCP.

The Chemistry Unit provides all essential components for early drug discovery such as synthesis of chemical intermediates, process impurities, reference compounds, drug metabolites, and pro-drug; lead generation and optimization; bioconjugate chemistry; targeted molecules for MRI and others Molecular Imaging techniques.

Ambiotis is a pre-clinical CRO specialized in the study of inflammatory processes and the active end of inflammation, called resolution. Resolution is now recognized as the necessary biological process to stop inflammation and restore homeostasis in tissues. This recent approach makes possible to study the inflammation process in a completely innovative and differentiating way.

Ambiotis proposes services adapted to pharmaceutical, dermo-cosmetic, agro- food/nutraceutical industries to evaluate the potential of their molecules at preclinical or clinical stages of development. Ambiotis thus helps them to put faster on the market more efficient and innovative compounds on immuno-inflammatory processes.

With more than 10 years of experience, Ambiotis has acquired a solid expertise in understanding the molecular mechanisms controlling these phenomenons . Ambiotis has built a strong expertise in both cell/animal models and analytical measurement. This combination is the key to ensure a full understanding and provide proof of efficacy or proof of concept for the development of new innovative products.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com